Arensia Clinics S.R.L.

The trials here

What the 35 trials at this site are about, from their registry records.

Conditions

• Rheumatoid arthritis7 trials
• Lupus (SLE)4 trials
• Asthma3 trials
• COPD3 trials
• Multiple sclerosis3 trials
• Chronic kidney disease2 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Immune thrombocytopenia (ITP)2 trials
• Macular degeneration2 trials
• Ulcerative colitis2 trials
• Alopecia areata1 trial
• Chronic lymphocytic leukaemia1 trial
• and 10 more

Phase

• Phase 118 trials
• Phase 28 trials
• Phase 37 trials
• Phase 1/22 trials

Status

• Recruiting13 trials
• Completed10 trials
• Active, not recruiting7 trials
• Not yet recruiting4 trials
• Suspended1 trial

Lead sponsor

• AstraZeneca2 trials
• Novartis Pharma AG2 trials
• Regeneron Pharmaceuticals2 trials
• Sanofi2 trials
• Amgen Inc.1 trial
• and 26 more

Running trials

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD

  2026-525216-34-00· Phase 2· Expedition Therapeutics Inc.· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis

  2025-524746-96-00· Phase 1· Jade Biosciences Inc.· Source

• Recruiting

  Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

  NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis

  2025-525113-22-00· Phase 1· Neurocrine Biosciences Inc.· Source

• Recruiting

  A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis

  NCT07433335· Phase 1· SciRhom GmbH· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)

  NCT07363590· Phase 1· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease

  2025-520978-18-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

  NCT07230834· Phase 1· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

  NCT07276724· Phase 3· Generate Biomedicines· Source

• Recruiting

  A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis

  2024-512914-16-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)

  2024-511346-39-00· Phase 1· Chugai Pharmaceutical Co. Ltd.· Source

• Active, not recruiting

  A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

  NCT06799520· Phase 1· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Recruiting

  A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

  NCT06842186· Phase 1/2· Wave Life Sciences USA, Inc.· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Cullinan Therapeutics Inc.· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Phase 1· Chugai Pharmaceutical· Source

• Active, not recruiting

  A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

  2022-501622-37-00· Phase 3· Celltrion Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

  NCT05946941· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Sanofi· Source

• Active, not recruiting

  The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

  NCT05540327· Phase 2· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

  NCT04879043· Phase 1/2· Heidelberg Pharma AG· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

  NCT05704361· Phase 1· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Rheumatoid arthritis4 recruiting
• COPD2 recruiting
• Lupus (SLE)2 recruiting
• Macular degeneration2 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Multiple myeloma1 recruiting
• Obesity1 recruiting
• Peripheral artery disease1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.

  2025-523051-64-00· Phase 2· Idorsia Pharmaceuticals Ltd.· Source

• Active, not recruiting

  An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

  NCT07052032· Phase 1· Candid Therapeutics· Source

• Recruiting

  Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

  NCT06980116· Phase 1· Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.· Source

• Completed

  A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

  NCT06675175· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

  NCT06676319· Phase 2· Sanofi· Source

• Completed

  Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

  NCT06551064· Phase 1· Formycon AG· Source

• Completed

  A study to investigate the safety, tolerability, and pharmacokinetics of Ent001 in patients with moderately to severely active ulcerative colitis

  2023-507340-36-00· Phase 1· Enthera S.r.l.· Source

• Completed

  MAD Study of IA-14069

  NCT05533372· Phase 1· ILAb Co., Ltd.· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

  NCT05251259· Phase 2· AstraZeneca· Source